Incorporation of a new biological marker such as HER2 into routine clinical practice requires proof that it provides reproducible information independent of, and better than, conventional pathologic criteria, and that it influences treatment decisions. In breast cancer, HER2 amplification/overexpression predicts for a poor clinical outcome and an enhanced survival benefit from the HER2-targeted therapy, Herceptin®, and may predict for resistance to some conventional therapies. Thus, HER2 is considered to be a clinically important molecule and testing for HER2 abnormalities is already part of routine patient assessment in many parts of the world. There is currently no gold standard for HER2 testing. The main challenge is to standardize and technically validate HER2 testing methodologies. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are the most common HER2 tests used, and show a high level of concordance. HER2 testing approaches based on the polymerase chain reaction (PCR) are under extensive investigation and appear promising. A Canadian HER2 testing algorithm designed to increase the validity and reproducibility of HER2 testing has been compiled. HER2-positive cases are defined as those with >10% of tumor cells with moderate/strong, complete membrane staining in the invasive component, by IHC. Confirmatory HER2 testing using either FISH or quantitative PCR is recommended for indeterminate cases. Additional studies are required to calibrate HER2 testing results to clinical outcome.

1.
Allred DC, Swanson PE: Testing for erbB-2 by immunohistochemistry in breast cancer. Am J Clin Pathol 2000;113:171–175.
2.
American Society of Clinical Oncology (ASCO): 1997 uptake of the recommendations of the use of tumour markers in breast and colorectal cancer. J Clin Oncol 1998;16:793–795.
3.
Bast RC Jr, Ravdin P, Hayes DF, Bates S, Fritsche H Jr, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:1865–1878.
4.
Bieche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M: Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148–1156.
5.
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639–2648.
6.
Deng G, Kim YS: Quantitation of erb-B-2 gene copy number in breast cancer by an improved polymerase chain reaction (PCR) technique, competitively differential PCR. Breast Cancer Res Treat 1999;58:213–217.
7.
Dowsett M, Cooke T, Ellis I, Gullick WJ, Gusterson B, Ballon E, Mallon E, Walker R: Assessment of HER2 status in breast cancer: why, when and how? Eur J Cancer 2000:36:160–176.
8.
Espinoza F, Anguiano A: The HercepTest assay: another perspective. J Clin Oncol 1999;17:2293–2294.
9.
Farabegoli F, Ceccarelli C, Santini D, Baldini N, Tafurelli M, Marrano D, Trere D, Derenzini M: c-erbB-2 overexpression in amplified and non-amplified breast carcinoma samples. Int J Cancer 1999;84:273–277.
10.
Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O’Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ: Prognostic Factors in Breast Cancer. Arch Pathol Lab Med 2000;124:966–978.
11.
Frye RA, Benz CC, Liu E: Detection of amplified oncogenes by differential polymerase chain reaction. Oncogene 1989;4:1153–1157.
12.
Gramlich TL, Cohen C, Fritsch C, DeRose PB, Gansler T: Evaluation of c-erbB-2 amplification in breast carcinoma by differential polymerase chain reaction. Am J Clin Pathol 1994;101:493–494.
13.
Hanna W, Kahn HJ, Trudeau M: Evaluation of HER-2/neu (erbB-2) status in breast cancer: from bench to bedside. Mol Pathol 1999;12:827–834.
14.
Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Yoshiyuki Osamura R, Tani Y: Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTest in breast carcinoma by image analysis. Pathol Internat 2001;51:33–36.
15.
Hayes DF, Bast R, Desch CE: A tumor marker utility grading system (TMUGS): a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456–1466.
16.
Hayes DF, Trock B, Harris AL: Assessing the clinical impact of prognostic factors: when is ‘statistically significant’ clinically useful? Breast Cancer Res Treat 1998;52:305–319.
17.
Henson DE, Fielding P, Grignon DJ, Page DL, Hammond ME, Nash G, Pettigrew NM, Gorstein F, Hutter RV: College of American Pathologists Conference XXVI on clinical relevance of prognostic markers in solid tumors. Arch Pathol Lab Med 1995;19:1109–1112.
18.
Higuchi R, Fockler C, Dollinger G, Watson R: Kinetic PCR: real time monitoring of DNA amplification reactions. Biotech 1993;11:1026– 1030.
19.
Hynes NE: Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy. Semin Cancer Biol 1993;4:19–26.
20.
Hynes NE, Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta Rev Cancer 1994;1198:165–184.
21.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. Am J Clin Pathol 2000;113:251–256.
22.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Comparison of fluorescence in-situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999a;17:1974–1982.
23.
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999b;17:1983–1987.
24.
Jacobs TW, Prioleau JE, Stillman IE, Schnitt SJ: Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst 1996;88:1054–1059.
25.
Jiminez RE, Wallis, T, Tabasczka P, Visscher DW: Determination of Her-2/Neu status in breast carcinoma: a comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Mod Pathol 2000;13:37–45.
26.
Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M: C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol 1994;47:816–822.
27.
Lehmann U, Glockner S, Kleeberger W, von Wasielewski HF, Kreipe H: Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000;156:1855–1864.
28.
Maia DM: Immunohistochemical assays for HER2 overexpression. J Clin Oncol 1999;17:1650.
29.
Mass RD, Sanders C, Charlene K, Johnson L, Everett T, Anderson S: The concordance between the clinical trials assay (CTA) and fluorescence in situ hybridisation (FISH) in the Herceptin pivotal trials. Proc Am Soc Clin Oncol 2000;19:75A.
30.
McGuire WL: Breast cancer prognostic factors: evaluation guidelines. J Natl Cancer Inst 1991;83:1–9.
31.
Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A: HER2 as a prognostic factor in breast cancer. Oncology 2001;61(suppl 2):67–72.
32.
Nelson NJ: Common techniques used to detect HER2. J Natl Cancer Inst 2000;92:293–294.
33.
Norton L, Slamon D, Leyland-Jones B, Wolter J, Fleming T, Eirmann W, Baselga J, Mendelsohn J, Bajamonde A, Ash M, Shak S: Overall survival (OS) advantage to Herceptin (H) in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1999;18:127A.
34.
Okuyama N, Hatano Y, Park Y, Shimatani S, Sasamoto S, Katou N, Takagi K, Yamazaki S, Inoue A, Hemmi H, Shimatake H, Yanagida M, Miura M: Quantitation of c-erbB-2 gene amplification in breast cancer tissue by competitive PCR. Tumour Biol 1999;20:153–161.
35.
O’Malley FP, Parkes R, Hanna W, et al: A Canadian interlaboratory concordance study of HER2/neu assessment by immunohistochemistry and FISH. Mod Pathol 2001;14:33A.
36.
Paik S, Bryant J, Park C, Fisher B, Tan-Chiu E, Hyams D, Fisher ER, Lippman ME, Wickerham DL, Wolmark N: Erb-B2 and response to doxorubicin in patients with axillary lymph node-positive, hormone-receptor-negative breast cancer. J Natl Cancer Inst 1998;90:1361–1370.
37.
Pauletti G, Godolphin W, Press MF, Slamon DJ: Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63–72.
38.
Penault-Llorca F, Adelaide J, Houvenaeghel G, Hassoun J, Birnbaun D, Jacquemier J: Optimization of immunohistochemical detection of ERBB” in human breast cancer: impact of fixation. J Pathol 1994;173:65–75.
39.
Persons DL, Bui MM, Lowery MC, Mark HF, Yung JF, Birkmeier JM, Wong EY, Yang SJ, Masood S: Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 2000;30:41–48.
40.
Piccart M, Awada A, Hamilton A: Integration of new therapies into management of metastatic breast cancer: a focus on chemotherapy, treatment selection through use of molecular markers, and newly developed biologic therapies in late clinical development. Am Soc Clin Oncol 1999;35th Annual Meeting, May 15–18, Atlanta. Educational Book 526–539.
41.
Piccart M, Lohrisch C, Di Leo A, Larsimont D: The predictive value of HER2 in breast cancer. Oncology 2001;61(suppl 2):73–82.
42.
Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771–2777.
43.
Ratcliffe N, Wells W, Wheeler K, Memoli V: The combination of in situ hybridization and immunohistochemical analysis: an evaluation of HER2/neu expression in paraffin-embedded breast carcinomas and adjacent normal-appearing breast epithelium. Mod Pathol 1997;10:1247–1252.
44.
Roche PC, Ingle JN: Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999;17:434.
45.
Ross JS, Fletcher JA: The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998;16:413–428.
46.
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–182.
47.
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707–712.
48.
Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Baselga J, Norton L: Addition of Herceptin™ (humanized anti-HER2 antibody) to first-line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998;17:98A.
49.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783–792.
50.
Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol 1989;7:1120–1128.
51.
Thor AD, Schwartz LH, Koerner FC, Edgerton SM, Skates SJ, Yin S, McKenzie SJ, Panicali DL, Marks PJ, Fingert AJ, et al: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 1989;49:7147–7152.
52.
Thor AD, Berry DA, Budman DR, Muss HB, Kute T, Henderson IC, Barcos M, Cirrincione C, Edgerton S, Allred C, Norton L, Liu ET: Erb-B2, p53 and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:1346–1360.
53.
Vogel CL, Cobleigh M, Tripathy D, Harris L, Fehrenbacher L, Slamon D, Ash M, Novotny W, Stewart S, Shak S: First-line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 2000;19:71A.
54.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ: First-line Herceptin® monotherapy in metastatic breast cancer. Oncology 2001;61(suppl 2):37–42.
55.
Vona G, Caldini A, Sestini R, Rapi S, Bianchi S, Fanelli A, Pazzagli M, Orlando C: The c-erbB-2 oncogene amplification by competitive PCR in aneuploid cell clones flow sorted from breast cancer samples. Clin Chem Lab Med 1999;37:649–654.
56.
Youngson BJ, Anelli A, Van Zee KJ, Borgen PI, Norton L, Rosen PP: Microdissection and molecular genetic analysis of HER2/neu in breast carcinoma. Am J Surg Pathol 1995:19:1354–1368.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.